Inovio secures FDA nod for phase 2 segment of Covid-19 DNA vaccine candidate trial
The phase 2 segment will evaluate the efficacy of Covid-19 DNA vaccine candidate called INO-4800 in adults in the US. Inovio’s study will be financed by the US
Oisín Biotechnologies has announced the initial close of its Series A financing raising $15m, earmarked for advancing its pipeline of therapies for age-related diseases.
Dr. Himanshu Pop Hale, Ace Hospital Pune, India, has recruited the first patient in the IPF phase II Proof-of-Concept study with C21 (VP01 project). “We are pleased to announce that
As part of single target research collaboration, both companies will conduct research activities to select a pre-clinical candidate after which Roche will focus on further development and global
NAVIGATOR met the primary endpoint with tezepelumab added to standard of care (SoC) demonstrating a statistically significant and clinically meaningful1 reduction in the annualized asthma exacerbation rate (AAER) over